Scientists say they have discovered a new class of treatment for Alzheimer's disease which could represent a "major breakthrough" in combating the condition.
The medicine appears to slow the progression of the disease by 81 per cent over the course of a year, according to researchers from the University of Aberdeen working with Singaporean company TauRx Therapeutics.
Rember was tested in a phase-two clinical trial involving 321 patients with mild to moderate Alzheimer's disease - with results suggesting that the drug had its greatest effect in the memory-critical regions of the brain where the effects of the condition are most pronounced.
Claude Wischik, professor of psychiatric geratology and old age psychiatry at the University of Aberdeen and chairman of TauRx Therapeutics, hailed the data as "unprecedented" in the field of Alzheimer's treatment.
He continued: "We have demonstrated for the first time that it may possible to arrest the progression of this disease by targeting the tangles which are highly correlated with the disease."
Separate research from the US recently published in the medical journal of the American Academy of Neurology has suggested that cholesterol-lowering drugs statins may offer some degree of protection against dementia.
Please click here to find a care home for elderly care.